
# GLOMERULAR DISEASE

# GLOMERULONEPHRITIS (GN)

## 定義 
> (_Lancet_ 2016;387:2036; _JASN_ 2016;27:1278)

• ↑ glomerular inflammation → endothelial & podocyte injury

• Histology: proliferative (↑ cells), sclerosing (scar), necrotizing (areas cell death). Focal (<50% of glomeruli) to diffuse to crescentic. Segmental (<50% tuft) to global (100%).

• Clinically: hematuria with dysmorphic RBCs or RBC casts, ± subnephrotic proteinuria

often with AKI, HTN, edema

• Progression: acute ≈ days; rapidly progressive (RPGN) ~6 wk; chronic ≈ mos; can be asx

• Crescentic GN (pathologic description) ≈ RPGN (臨床description)

![](https://i.imgur.com/KIj1Y2l.jpg)

a Predominant type; p- or c-ANCA can be in all (_NEJM_ 2012;367:214); bGPA (Wegener’s); EGPA (Churg-Strauss)

![](https://i.imgur.com/NHlkiAX.jpg)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Immune Complex (IC) Disease (granular staining) ~40–45% of total</b> <span>(</span><span><i>CJASN</i></span> <span>20</span><span>1</span><span>8;</span><span>1</span><span>3:</span><span>1</span><span>28)</span></p></td></tr><tr><td><p><b>Renal-limited Diseases</b></p></td><td><p><b>Systemic Diseases</b></p></td></tr><tr><td><p><b>Infection-related GN</b></p><p>(<i>Staph</i> &amp; <i>Strep;</i> ↓ C3, ± ASLO)</p></td><td><p><b>SLE</b> (<i>CJASN</i> 2017;12:825)</p><p>(⊕ ANA, ⊕ anti-dsDNA, ⊕ anti-Sm, ↓ C3, ↓ C4)</p></td></tr><tr><td><p><b>Membranoproliferative GN</b> (MPGN) (↓ C3)</p></td><td><p><b>Cryoglobulinemia</b></p><p>(⊕ cryocrit, ⊕ RF, ⊕ HCV, SPEP, ↓ C3, ↓ C4)</p></td></tr><tr><td><p><b>Fibrillary and immunotactoid GN</b> (normal C3/C4)</p></td><td><p><b>Endocarditis</b></p><p>(fever, ⊕ BCx, valvular disease, ↓ C3)</p></td></tr><tr><td><p><b>IgA nephropathy</b> (normal C3, ±↑ IgA)</p><p><span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>3;368:2402;</span> <span><i>CJASN</i></span> <span>20</span><span>1</span><span>7;</span><span>1</span><span>2:677)</span></p></td><td><p><b>Henoch-Schönlein purpura</b> (IgA nephropathy + syst. vasculitis with IgA deposits, 正常 C3, ±↑ IgA)</p></td></tr></tbody></table>

## Oncology-related glomerulopathy 
> (_CJASN_ 2016;11:1681)

• Associations between malig (solid tumors & heme) and/or their Rx (HSCT & chemo-therapeutics) and GN, nephrotic syndrome, and thrombotic microangiopathies (TMA)

• Most common associations: membranous (solid tumors, HSCT), MCD (Hodgkin’s, solid tumors), MPGN (CLL, MM), TMA (HSCT, VEGF, anti-EGFR, CNIs, TKIs, mTOR)

• **Monoclonal glomerulopathy of renal significance:** Ig-mediated kidney disease by nonmalignant B or plasma cells. Workup: SPEP, sFLC, flow cytometry, IFE, BMBx.

## Workup (_JAMA_ 2017;318:1276)

• _Acute GN/RPGN_ ± _lung hemorrhage is an emergency_ → requires early Dx and Rx

• UA + sediment (dysmorphic RBCs) ✔ ANCA, anti-GBM, C3/C4, SPEP, serum FLC

• Depending on hx: ANA, anti-dsDNA/Sm, RF, Hep B&C, HIV, ASLO, BCx, cryocrit, skin bx

• Consider GN mimics: thrombotic microangiopathies (qv), myeloma, AIN, cholesterol emboli

• Renal biopsy with immunofluorescence (IF) ± electron microscopy (EM)

### Figure 4-8 Approach to glomerulonephritis based on immunofluorescence pattern

![](https://i.imgur.com/VvcYTsj.jpg)

## 治療 (_CJASN_ 2017;12:1680)

• If acute GN/RPGN suspected, give 500–1000 mg methylpred. IV qd × 3d _as soon as possible_ while awaiting bx results. Consider plasmapheresis & further Rx based on underlying disease.

• SLE nephritis: induction with steroids + cyclophosphamide (CYC) or MMF (_CJASN_ 2017;12:825)

• ANCA ⊕ or anti-GBM: pulse steroids + CYC (or rituximab). Plasma exchange if severe AKI or pulm hemorrhage (_JASN_ 2007;18:2180; _NEJM_ 2010;363:221; _AJKD_ 2011;57:566).

• See “Vasculitis” for further disease-specific 治療 details

# ASYMPTOMATIC GLOMERULAR HEMATURIA

## 定義 and 原因

• Hematuria ± proteinuria of glomerular origin without renal insufficiency or systemic disease (nonglomerular more common; see “Hematuria”)

• Ddx: any cause of GN (esp. IgA); also consider Alport’s (X-linked, deafness, renal failure), thin basement membrane nephropathy (autosomal dominant, benign; _JASN_ 2013;23:364)

## IgA nephropathy 
> (_NEJM_ 2013;368:25; _CJASN_ 2017;12:677)

• Most common cause of GN; ♂ pred; peak incidence 20–30s; can also be post-infectious

• Wide range of 臨床presentations: asx hematuria (30–40%), gross hematuria ~1–3 d

after URI (10–15%), chronic GN (10%), nephrotic syndrome (5%), RPGN (<5%)

• Though 臨床presentation can be highly suggestive, definitive dx only with bx

• Prognosis: ↑Cr, HTN, proteinuria a/w poor prog. (_AJKD_ 2012;59:865). 20–40% ESRD within 20 y.

• Rx: ACEI/ARB (_JASN_ 1999;10:1772); steroids if persistent proteinuria (> 1g/d; _NEJM_ 2015;373: 2225); ± cytotoxic Rx for crescentic GN or HTN & ↑ Cr (_JASN_ 2012;23:1108); ? fish oil

# NEPHROTIC SYNDROME

## 定義 (_JASN_ 2014;25:2393)

• Podocyte injury (effacement) → loss of proteins (albumin, ATIII, Ig)

• Clinically: proteinuria >3.5 g/d, albumin <3 g/dL, edema, ↑ chol., VTE (25%), infection

## Primary glomerular diseases (grouped by pathology)

• **Focal segmental glomerulosclerosis** (40%; _CJASN_ 2017;12:502): 1° (cytokine mediated); _adaptive_ (hyperfiltration, sickle cell, obesity, anabolic steroids, OSA, ↑ protein, vesico-ureteral reflux); _genetic_ (_ApoL1_ mutation in AA (_JASN_ 2015;26:1443); _viral_ (HIV most strongly associated); _meds/toxins_ (IFN, bisphosphonates, NSAIDs, heroin)

• **Membranous nephropathy** (30%; _Lancet_ 2015;385:1983; _CJASN_ 2017;12:938): 1° (Ab to PLA2R \[70%\] or THSD7A \[5%\]; _NEJM_ 2014;371:2277); _infection_ (HBV, HCV, HIV, syphilis); _autoimmune_ (eg, SLE); _carcinomas_; _drugs_ (NSAIDs, penicillamine)

• **Minimal change disease** (20%, more common in children; _CJASN_ 2017;12:332)

allergies, NSAIDs, ampicillin, Hodgkin’s disease, SLE, DM, MG, celiac disease

• **Membranoproliferative GN** (5%, _mixed_ nephrotic/nephritic features; _CJASN_ 2014;9:600)

Immune complex mediated: infection (esp. HCV ± cryos, IE, HBV, “shunt” nephritis, other chronic infxns), SLE, cryos, Sjögren’s, lymphomas, dysproteinemia, idiopathic

Complement mediated (rare); dense deposit disease (DDD), C3GN

• **Fibrillary-immunotactoid glomerulopathy** (1%; _JASN_ 2008;19:34)

• **Mesangial proliferative GN** (? atypical forms of MCD/FSGS, 5%) IgM, C1q nephropathy

## Systemic diseases with secondary glomerular involvement

• **Diabetes mellitus** (_CJASN_ 2017;12:2032): nodular glomerulosclerosis (Kimmelstiel-Wilson lesion); glomerular hyperfiltration → microalbuminuria → dipstick ⊕ → nephrotic range (10–15 y). Proliferative retinopathy seen in 90% of type 1 and 60% of type 2.

• **Amyloidosis:** AL or light-chain amyloid or AA amyloid secondary to inflammation

• **SLE** (_CJASN_ 2017;12:825): typically membranous nephropathy (WHO class V)

• **Cryoglobulinemia** (AJKD 2016;67): a/w HCV, monoclonal gammopathy. Typically MPGN.

## Workup (_BMJ_ 2008;336:1185)

• U/A + sediment: usually benign; ± oval fat bodies (“Maltese crosses”; _NEJM_ 2007;357:806)

• Measure proteinuria: 24-h urine or spot urine protein/Cr ratio (not accurate in AKI), renal bx

• 2° causes: ↑ HbA1C + retinop. → DM; ✔ ANA, anti-dsDNA, tox screen, C3/C4, SPEP/light chains, fat pad bx, cryocrit, HBV/HCV, HIV, RPR, APLA2R Ab, age-approp. CA screen

## 治療 (_NEJM_ 2013;368:10)

• General: protein suppl.; diuretics for edema; treat hyperlipidemia, Na restriction (<2 g/d)

• **ACEI** or **ARB:** ↓ proteinuria → slow nonimmunologic progression of renal disease

• 1° glomerular: steroids ± cytotoxic therapy (_KI_ 2012;2:139; _CJASN_ 2014;9:1386)

• Secondary causes: treat underlying disease

• Watch for malnutrition (protein loss), consider anticoag if albumin <2.5 in membranous (_KI_ 2014;85:1412), infection (esp. encapsulated organisms b/c loss of Ig)
